January 12, 2018 · Cancer Research · (No comments)

There might be more articles about Oncotarget today than there is possibly available time to read them all. Sure, you can find digests and summaries, but most of them are just fillers that can’t give you the information that you need. In this article, we will attempt to change that. We will show you that you don’t need a long article to know the latest things happening to Oncotarget. All you need is one. Here’s the one:

The Oncotarget Research On lncRNA and NKFBIA

In one of the ResearchGate articles today, you may find a summary of what Oncotarget was able to publish involving LncRNA LINC00936 and the target that it has on Myocardial Infarction. In the research, it was intimated that the NF-KB signaling pathway in vivo and vitro study would mean a whole lot of changes and development in the lives of the suffering patient. Learn more about Oncotarget at Eurekalert.org.

In the research, it was shown that there are now present ways in how cell proliferation is affected in the bodies’ expression levels. There’s also a lot of talk in Oncotarget about Cell Proliferation and Flow Cytometry Analysis, which confirmed a lot of the changes that needed to be done to maintain proper cell endometriosis in the body.

In the research, it was also concluded that lncRNA LINC00261 would definitely be capable of inhibiting migration and cell growth in a standard endometriosis. Follow Oncotarget on Twitter.

About Oncotarget

One of the many things you should also learn about Oncotarget is the report that it has in Eureka Alert, which ieatures the story about how Oncotarget is leading in the study of finding a remedy to thyroid cancer that won’t probably cause a lot of worry and side effects to the suffering patient.

That said, Oncotarget is able to consider a lot of things that are needed to make sure that the remedy for thyroid cancer can be addressed. In the Eureka Alert, it was also shown that most of the research work done by Oncotarget had been reviewed by many researchers and data experts whose reputation and expertise are unmatched.

That said, it might be easy to consider Oncotarget as one of the leading publishing bodies today that can find the answers to people’s biggest medical questions.

Know more: https://www.researchgate.net/journal/1949-2553_Oncotarget

November 22, 2017 · Cancer Research · (No comments)

The Siegall’s ambitions are manifested in his aspiration to go past the focus of biotech’s drug development towards taking care of all complexities of the worldwide market for its new drugs. This is a perfect repeat of what the company did during its earlier years when it sold its global commercial rights to Takeda Oncology to get funds to research Adcetris. Once he had learned about the international markets through its collaboration with Takeda, Siegall opened an office in Switzerland to let Seattle genetics conduct its global marketing.

In another emblem to its great determination to the international market, Siegall presented a proposal to utilize $2 billion to purchase the worldwide rights and commercialize a cancer drug established by Immunomedics located in New Jersey. However, Siegall was forced to withdraw the offer in May when a judge made a verdict that the transaction will not go through since there was an unrelated tussle for management over the Immunomedics’ board. However, the struggle signaled the commitment of Seattle genetics to utilize its understanding of oncology to obtain the rights to sell the new drugs in the global market.

The company has been focusing on the particular type of drug called an antibody-drug conjugate, or ADC. In most cases, the drug aims the protein molecule that triggers an immunize system to produce antibodies. The antigens attach themselves to the outside of cancer cells and other deadly disease and deliver a toxin in the cell to destroy them. The role of the ADC is to provide a payload to kill the cancer cells while not having a negative impact on the normal tissues. Typically, the approach significantly lessens the collateral damage that can result in healthy cells in when a patient is going through the traditional chemotherapy and radiation. In all the 11 drugs found in the Seattle Genetics pipeline, Siagall claims that four of them have massive potential for the most instant sales.

About Clay Siegall

Currently, Clay Siegall works as the president, CEO of Seattle Genetics, a biotech firm that specializes in the development and commercialization of innovative antibody related therapies for the cure of cancer. He is also the co-founder of the company that was established in 1998. Before engaging in Seattle Genetics, Siagall served the Bristol-Myers Squibb Pharmaceutical research institute from 1991 to 1997. He also worked at national cancer institute and national institute of health from 1988 to 1991. Dr. Siagall obtained a B.S in Zoology from Maryland University and a Ph.D. in Genetics from the University of George Washington.

Have you come across the name Eric Lefkofsky? If no, then you are in the right place. Eric became famous when working at Inner Workings and Echo Global Logistics. However, it is his third company that made him recognizable.Eric earned more than 1.79 million dollars with e-commerce startups but still aspired to do better. He recently started his latest company Tempus, and it has a great goal. Tempus is going to assemble an extensive genomic cancer database. With this data bank, doctors will be able to compare the DNAs of their patients so they can personalize their therapies. With this help and the best cancer specialists will be able to help cancer patients live longer or even get the cure.Eric realized that modern technology is growing fast and it was fair for technology in the medical field to progress at the same speed. He figured that doctors were collecting data and they needed a way to analyze it.

Many startups are trying to find a cure for diseases due to growth in technology. The industry has therefore grown because it is not expensive to conduct tests as it was before. However, despite all this Eric trusts that Tempus is advantageous over other companies.To ensure that Tempus remains on top, they collaborated with several hospitals. They work together to collect massive amounts of data. Tempus has built a 20,000 –square-foot lab to enable gene-sequencing lab. They provide their specialists with software that allows them to make comparisons of DNA profiles of cancer patients. Through this, they will find cures that would work best for patients with detailed hereditary profiles.

In 2015, Eric quit being the CEO of Groupon to concentrate on building Tempus into a global firm. However, he is still the chair of Groupon and the largest shareholder. His first action as the Tempus leader was to hire Kevin White who is highly skilled in the genetic industry.In conclusion, Eric co-owns Tempus with his business partner Brad Keywell. They have worked together in many business ventures as well.